U.S. Markets closed

FBI agent Strzok, who criticized Trump in text messages, is fired

By Sarah N. Lynch

By Sarah N. Lynch

WASHINGTON (Reuters) - Peter Strzok, the FBI agent who came under fire from President Donald Trump and other Republicans for sending text messages that disparaged the candidate during the presidential campaign, was fired late on Friday, his attorney said on Monday.

Strzok is the third high-ranking person to be fired from the Federal Bureau of Investigation during the Trump administration, including former Director James Comey. During his FBI career, Strzok rose to deputy assistant director, focusing on counterintelligence.

After Justice Department internal investigators found the texts, Strzok was reassigned from Special Counsel Robert Mueller's investigation into the Trump campaign. The firing came after a lengthy internal investigation.

Strzok's attorney, Aitan Goelman, said in a statement that FBI Deputy Director David Bowdich made the decision to terminate his client.

The decision, Goelman added, was at odds with a recommendation by the FBI's Office of Professional Responsibility, which had called for Strzok to face a 60-day suspension and demotion from his supervisory responsibilities.

He also said it went against promises that FBI Director Christopher Wray made in the past about adhering to proper processes on personnel matters.

The FBI said in a statement it had followed its standard review and disciplinary process after the inspector general referred the Strzok case to the FBI's Office of Professional Responsibility.

"OPR reviewed the investigative materials, as well as the written and oral responses of Mr. Strzok and his counsel, and issued OPR's decision. The deputy director, as the senior career FBI official, has the delegated authority to review and modify any disciplinary findings ... as deemed necessary," the statement said.

Strzok's attorney Goelman, however, said that normally FBI personnel can appeal such decisions to a five-person review board. Goelman said the appeals step was bypassed in Strzok's case and the FBI did not follow the normal course afforded to other FBI agents.

Trump took to Twitter not long after the news broke on Monday.

"Agent Peter Strzok was just fired from the FBI-finally," wrote Trump, who had called for Strzok's ouster before.

"The list of bad players in the FBI & DOJ gets longer & longer."

A post under a newly created Twitter account under Strzok's name said he was "deeply saddened" by the decision to fire him.

The post also linked to a GoFundMe page, which had raised more than $48,700 toward a $150,000 goal as of late Monday.

"All funds raised on this GoFundMe will be put into a trust dedicated to covering Pete’s hefty – and growing – legal costs and his lost income," the fundraising website says.

Goelman said that his client's firing was politically motivated and that his texts represented political speech protected by the First Amendment.

'RUSSIA THING'

In March, Attorney General Jeff Sessions fired FBI Deputy Director Andrew McCabe after a scathing report by the Justice Department's internal watchdog concluded he had leaked information to reporters and misled investigators about his actions.

Comey was fired by Trump in May 2017 after Deputy Attorney General Rod Rosenstein helped write a memo that was critical of how Comey handled the FBI's probe into then-Secretary of State Hillary Clinton's use of a private email server for official business.

Later, however, Trump claimed he fired Comey over that "Russia thing," apparently referring to the FBI probe into whether his presidential campaign colluded with Russia. Trump has repeatedly denied any collusion and called the investigation a witch hunt.

Both Comey and McCabe said, however, they believe they were fired because they are key witnesses in Special Counsel Mueller's probe into whether Trump may have tried to obstruct the investigation.

Strzok was deeply involved in the FBI's Clinton email investigation and was temporarily assigned to Mueller's office. He was removed from that post after his texts came to light.

The texts were criticized by the Justice Department's inspector general in a recent report that examined the FBI's handling of the Clinton email probe. Republicans in Congress have repeatedly pointed to them as evidence the FBI is biased against Trump.

(Reporting by Sarah N. Lynch; editing by Jeffrey Benkoe, Jonathan Oatis, David Alexander and Cynthia Osterman)

  • Here's Why StoneCo Stock Is Plunging Today
    Business
    Motley Fool

    Here's Why StoneCo Stock Is Plunging Today

    Shares of Brazilian fintech company StoneCo (NASDAQ: STNE), which gained notoriety in recent months after being added to Berkshire Hathaway's portfolio, are plummeting today. Generally speaking, moves like this are often seen after earnings announcements, but StoneCo isn't set to report earnings again for another couple months. In this case, the plunge appears to be triggered by a move from a rival company.

  • Business
    Associated Press

    Fidelity Southern: 1Q Earnings Snapshot

    Fidelity Southern Corp. LION) on Thursday reported first-quarter earnings of $6.1 million. The bank, based in Atlanta, said it had earnings of 22 cents per share.

  • 10 Reasons to Buy Twilio Stock and Never Sell
    Business
    Motley Fool

    10 Reasons to Buy Twilio Stock and Never Sell

    The number of active customers using Twilio's platform to communicate with their clients has increased four-fold in four years. Concurrently, base revenue -- which excludes low-margin professional services and customers that don't sign long-term contracts -- has exploded. All of this is to say: Twilio has been an extremely popular option over the past five years.

  • Why Chico's FAS, Inc.'s (NYSE:CHS) Return On Capital Employed Looks Uninspiring
    Business
    Simply Wall St.

    Why Chico's FAS, Inc.'s (NYSE:CHS) Return On Capital Employed Looks Uninspiring

    Today we are going to look at Chico's FAS, Inc. (NYSE:CHS) to see whether it might be an attractive investment prospect. Specifically, we'll consider its Return On Capital Employed (ROCE), since that will give us an insight into how efficiently the business can generate profits from the capital it requires. Firstly, we'll go over how we calculate ROCE.

  • Are Investors Undervaluing Occidental Petroleum Corporation (NYSE:OXY) By 42%?
    Business
    Simply Wall St.

    Are Investors Undervaluing Occidental Petroleum Corporation (NYSE:OXY) By 42%?

    Today we will run through one way of estimating the intrinsic value of Occidental Petroleum Corporation (NYSE:OXY) by taking the expected future cash flows and discounting them to today's value. We generally believe that a company's value is the present value of all of the cash it will generate in the future. Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model.

  • Boeing Is About To Reveal How Much The 737 Max Crisis Is Really Costing
    Business
    Investor's Business Daily

    Boeing Is About To Reveal How Much The 737 Max Crisis Is Really Costing

    The embattled aerospace giant reports first-quarter results Wednesday, giving investors a first look at how much the grounding of the 737 Max jet has hit Boeing earnings so far — and will affect them later this year. Boeing stock has already fallen 14% from a recent high. Boeing's commercial aircraft have an outsized impact on the company's financials.

  • Here's Why Blackstone Shares Jumped on Thursday
    Business
    Motley Fool

    Here's Why Blackstone Shares Jumped on Thursday

    Shares of Blackstone Group (NYSE: BX) climbed nearly 7% on Thursday morning after the alternative asset manager reported first-quarter earnings that blew past expectations and announced plans to convert to a corporation from a partnership. Blackstone, before markets opened, said it had earned $0.71 per share in the first quarter, easily surpassing the consensus estimate for $0.53 per share in earnings. The partnership structure has prevented some classes of investors, namely pension funds and other tax-exempt institutions, from buying shares of Blackstone, and has made the company ineligible for inclusion on certain indexes.

  • Business
    Barrons.com

    GE Stock Got a Thumbs Up From a Mysterious 'Smartest Man'

    GE)'s beaten-down stock is up 25% year to date, and Melius Research analyst Scott Davis says the smartest industrial investor he knows is buying the shares. That's a tantalizing statement. Who is this investing star?

  • This Marijuana Stock Offers the Best Bang for the Buck
    Business
    Motley Fool

    This Marijuana Stock Offers the Best Bang for the Buck

    Companies like Cronos Group, which sports a $5.2 billion market cap, is only capable of perhaps 120,000 kilos of peak production, and is valued at north of 210 times forward earnings. Similarly, Aurora Cannabis, Canada's projected leading producer at 780,000 kilos a year at peak capacity, may not even be profitable in fiscal 2020 due to expansion costs. Yet it's lugging around an $8.5 billion valuation.

  • Investors sue Lyft with claims of "overhyped" IPO
    Business
    Yahoo Finance Video

    Investors sue Lyft with claims of "overhyped" IPO

    Investors are taking Lyft to court. Two separate class-action suits were filed yesterday, claiming that the ride-hailing company overstated its market position when it went public last month, according to a Bloomberg report. Yahoo Finance's Adam Shapiro and Julie Hyman discuss with the panel.

  • Have Insiders Been Buying Evoqua Water Technologies Corp. (NYSE:AQUA) Shares This Year?
    Business
    Simply Wall St.

    Have Insiders Been Buying Evoqua Water Technologies Corp. (NYSE:AQUA) Shares This Year?

    It is not uncommon to see companies perform well in the years after insiders buy shares. It's quite normal to see company insiders, such as board members, trading in company stock, from time to time.

  • Will T2 Biosystems, Inc.'s (NASDAQ:TTOO) Earnings Grow In The Years Ahead?
    Business
    Simply Wall St.

    Will T2 Biosystems, Inc.'s (NASDAQ:TTOO) Earnings Grow In The Years Ahead?

    The latest earnings update T2 Biosystems, Inc. (NASDAQ:TTOO) released in December 2018 suggested company earnings became less negative compared to the previous year's level - great news for investors Below, I've laid out key growth figures on how market analysts view T2 Biosystems's earnings growth outlook over the next few years and whether the future looks brighter. This means, we can expect T2 Biosystems will grow its earnings by 37% every year for the next couple of years.

  • Why Nintendo Stock Popped Today
    News
    Motley Fool

    Why Nintendo Stock Popped Today

    What happened Shares of Nintendo (NASDAQOTH: NTDOY) were up 13.6% as of 1:30 p.m. EDT Thursday after news emerged that the company's Switch gaming console will soon begin selling in China. But Nintendo won't be selling the devices directly.

  • Snap Stock Downgraded Twice in 1 Day: What You Need to Know
    Business
    Motley Fool

    Snap Stock Downgraded Twice in 1 Day: What You Need to Know

    Wedbush thinks this expectation is already factored into Snap's higher share price, and therefore rates the stock only neutral, with a $12.25 price target. Downgrading Snap stock, part deux Vertical Group is even more pessimistic, observing in a note covered by StreetInsider.com (subscription required) that Snap is experiencing "stagnant" return on its investments, and cutting spending (because without returns, what's the point? in order to conserve cash.

  • Health-care drama has now spread to biopharma stocks
    Business
    MarketWatch

    Health-care drama has now spread to biopharma stocks

    Health stocks had another bad day, with investor jitters spreading to the biotech and pharmaceutical sectors, as well. Investors' anxiety seemed to have expanded from health retailers, managed care companies and health insurers to include biopharma companies on Thursday. The three biggest losers in the Health Care Select Sector SPDR Fund ETF (XLV) were Regeneron Pharmaceuticals Inc.

  • Why Mustang Bio Stock Is On Fire Today
    News
    Motley Fool

    Why Mustang Bio Stock Is On Fire Today

    Mustang's shares are blasting off in response to the news that an experimental gene therapy, MB-107, for "bubble boy" disease -- also known as X-linked severe combined immunodeficiency, or XSCID for short -- reportedly cured eight boys with the deadly condition. Equally critical, Mustang said that the boys are showing no signs of unintended side effects from the therapy -- an issue that has derailed prior gene therapies for XSCID. Mustang licensed MB-107 from St. Jude Children's Research Hospital.

  • Why the Zoom and Pinterest IPOs matter so much for valuations
    Business
    Yahoo Finance Video

    Why the Zoom and Pinterest IPOs matter so much for valuations

    Zoom and Pinterest both began trading on the public market today. Yahoo Finance's Zack Guzman and Kristin Myers are joined by Lauren Smith Brody, 'The Fifth Trimester' author and founder, and Barrett Daniels, Deloitte & Touche National IPO Services Leader, to discuss why both IPOs matter so much for valuations.

  • Why Century Aluminum Stock Dropped Today
    Business
    Motley Fool

    Why Century Aluminum Stock Dropped Today

    But here's the thing: While this is "earnings season," a time of year we've been trained to expect to see big rises (and falls) in our stocks, Century Aluminum hasn't reported earnings yet. In fact, it's not expected to report earnings until April 30. Unfortunately, while Century hasn't yet reported, Alcoa (NYSE: AA) just did -- and it seems that Alcoa's bad news is turning out to be even worse news for Century.

  • Here's Why Shares of Uxin Climbed Higher on Thursday
    Business
    Motley Fool

    Here's Why Shares of Uxin Climbed Higher on Thursday

    Chinese online used-car dealer Uxin's (NASDAQ: UXIN) volatile week continued on Thursday, with shares up more than 11% as the market continues to digest, and at least for now dismiss, a critical short-seller report that temporarily sent shares crashing. Shares of Uxin lost more than half of their value midday Tuesday after J Capital Research analyst Anne Stevenson-Yang issued a report claiming that Uxin has exaggerated the volume of auto sales it processes by as much as 40%, and that founder and CEO Kun Dai was making false statements about the business' strength while taking cash out of the business. The response helped Uxin shares to recover much of what they lost on Wednesday.

  • COPD space about to have another drug — this time from a Morrisville concern
    Business
    American City Business Journals

    COPD space about to have another drug — this time from a Morrisville concern

    A recent FDA approval has one Triangle pharmaceutical company going head to head with the likes of pharma giants such as GSK – in a multi-billion dollar industry company officials believe they have the edge in. Circassia, a pharmaceutical company that calls Morrisville home to its U.S. headquarters, received FDA approval for Duaklir Pressair – a drug the treatment of patients with chronic obstructive pulmonary disease (COPD). Circassia's David Acheson, senior vice president of commercial business in the U.S., says the drug is scheduled to launch in the fourth quarter, because the company choose to wait for approval before beginning production preparations.

  • Why Check Point Software Stock Dropped 8% Today
    Business
    Motley Fool

    Why Check Point Software Stock Dropped 8% Today

    Shares of IT security specialist Check Point Software Technologies (NASDAQ: CHKP) plunged more than 11% in early trading on the Nasdaq today before retracing to about an 8.2% loss as of 12:40 p.m. EDT. Check Point reported its fiscal first-quarter 2019 earnings this morning, but earnings weren't the problem this time -- guidance was. An earnings beat could have sent Check Point stock up today.

  • Harry Boxer: Two marijuana stocks are among charts worth watching
    Business
    MarketWatch

    Harry Boxer: Two marijuana stocks are among charts worth watching

    Marijuana stocks are among our top charts to watch today. Bank of America Merrill Lynch named the company as one of three marijuana stocks to buy. The stock, after sharp year-to-date gains, has been consolidating in recent weeks, but may be on the verge of its next leg up with cannabis stocks in general.

  • Kinder Morgan Delivers Solid First-Quarter Performance
    Business
    Motley Fool

    Kinder Morgan Delivers Solid First-Quarter Performance

    Kinder Morgan's (NYSE: KMI) first-quarter results came in about as expected. The solid start to 2019 has the company on pace to hit its full-year budget for cash flow. It also allowed Kinder Morgan to fulfill its promise to boost the dividend by 25%.

  • Boeing 'shielded' from 737 Max order cancellations
    Business
    MarketWatch

    Boeing 'shielded' from 737 Max order cancellations

    Don't expect Boeing Co. to face a slew of order cancellations following the 737 Max debacle. Airlines, Boeing's (BA) main customers, are hungry for fuel-efficient single-aisle aircraft such as the Max, and there's a long backlog for the jet's closest competitor, Airbus SE' (FR:AIR) A320neo, analysts at Oxford Economics said in a note Thursday. “That will shield Boeing from a mass cancellation of orders,” the analysts said.

  • Is Aphria a Buy on the Dip?
    Business
    Motley Fool

    Is Aphria a Buy on the Dip?

    Shares of Aphria (NYSE: APHA) have tumbled about 16% since the company reported earnings results for its fiscal third quarter. This was the first full quarter since the company and its peers began selling adult-use recreational marijuana in Canada, and investors enthusiastic about the future are wondering if the market has overreacted and created a bargain opportunity. Let's take a closer look at the road ahead of Aphria to see if this troubled marijuana stock is a buy right now.